Chinese drug makers put on brave face after report says Trump mulling curbs on US licensing

The Trump administration's reported consideration of an executive order to curb US licensing of China-developed medicines led to a significant plunge in shares of Hong Kong-listed Chinese drugmakers. However, pharmaceutical executives at BioHK 2025, including Grand Pharmaceutical Group CEO Zhou Chao, downplayed the potential fallout, expressing skepticism about the order's feasibility given the extensive "licensing out" deals with major Western firms like Pfizer and AstraZeneca, and Chinese companies' continued investment in US clinical trials and drug development.

Analysis

A report suggesting the Trump administration may curb US licensing of China-developed medicines triggered a significant sell-off in Hong Kong-listed Chinese drugmakers, highlighting a major geopolitical risk for the sector. Despite the immediate negative market reaction, such as Grand Pharmaceutical Group's 3.2% share price decline, industry executives are publicly projecting confidence. Grand Pharma's CEO, Zhou Chao, expressed skepticism about the feasibility of a broad executive order, citing the deep integration with major Western pharmaceutical companies like Pfizer, AstraZeneca, and Bristol Myers Squibb through extensive 'licensing out' agreements. This sentiment is supported by Grand Pharma's own operational reality, which includes nearly US$200 million in revenue from the American market and an ongoing commitment to US-based clinical trials. The context of Grand Pharma's stock having nearly doubled in 2025 prior to this event suggests strong underlying fundamentals, which now face the uncertainty of potential US trade policy shifts.

Key Decisions for Investors

• Investors holding Chinese pharmaceutical stocks should closely monitor any official statements or draft orders from the US government, as this geopolitical headline risk is the primary driver of current volatility.
• It is crucial to differentiate between companies; firms with deep partnerships with major Western pharmaceuticals and significant existing US operations may be more insulated or have stronger lobbying power against such restrictions.
• The sharp share price decline could present a tactical buying opportunity in fundamentally strong companies for investors with a high-risk tolerance, contingent on the assessment that the proposed executive order is unlikely to be implemented or will be limited in scope.